Company intelligence

CTNM

Contineum Therapeutics, Inc. Class A Common Stock · NASDAQ · Healthcare

Price$14.82+0.00% · +$0.00

Market cap557.55MEquity value

P / E-8.6Trailing ratio

Volume601.13KLatest session

Market data

CTNM price chart

TradingView

Related signals

1 min delayed

Browse public CTNM signals with their source context and measured market impact. Open any signal for its permanent analysis page.

CTNMNov 21, 2025-0.81% since signal

Contineum Therapeutics' Multiple Sclerosis Trial Disappoints, But Analyst Sees Other Assets Driving Value

CTNM's Phase 2 VISTA trial for PIPE-307 showed no efficacy. The trial met safety metrics but missed primary/secondary endpoints. RBC Capital lowered CTNM's price forecast from $25 to $22. CTNM's stock dropped 13.26% following the negative trial results. Future prospects depend on PIPE-791 in idiopathic pulmonary fibrosis.

View signal analysis

Research